12 month, prospective, randomised, open-label comparative study to evaluate the protection of kidney function by basiliximab in a CNI-free regimen in newly kidney transplanted patients (three months post-transplant) who are recipient of one kidney from expanded donor criteria (UNOS criteria)
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Basiliximab (Primary) ; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms EXTEND
- 25 Nov 2006 New trial record.